New oral anticoagulants do not differ significantly in safety and efficacy from enoxaparin .
This report has been verified
by one or more authors of the
original publication.
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons
BMJ. 2012 Jun 14;344:e3675. doi: 10.1136/bmj.e3675A meta-analysis of 16 randomized trials (38747 patients) was conducted to investigate the effects of new oral anticoagulants (rivaroxaban, dabigatran, and apixaban), compared with standard enoxaparin, for prophylaxis against venous thromboembolism after total hip or knee replacement surgery. After investigating relative risks of symptomatic venous thromboembolism, clinically relevant bleeding, and deaths, the anticoagulants did not differ in net clinical endpoint (a balance of efficacy and safety). Generally the results demonstrated that the higher the efficacy of a treatment, the higher the risk of bleeding tendency.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
